A consortium of investors led by CVC Capital Partners has acquired a controlling stake in Alvogen. The deal reportedly values the company at roughly $2 billion. With 2,300 employees and commercial operations in 35 countries, Alvogen is a pharmaceuticals company focused on developing, manufacturing and selling generic, brand, OTC brands and biosimilar products. It currently has over 200 strategically selected pharmaceutical projects in development and registrations, as well as 350 marketed products. The controlling stake was purchased from Pamplona Capital Management and Aztiq Pharma. Willkie Farr & Gallagher served as exclusive legal advisor to Vatera in connection with the transaction.